Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

This study has been completed.
Sponsor:
Collaborator:
Vanda Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01348100
First received: April 28, 2011
Last updated: December 17, 2013
Last verified: December 2013

April 28, 2011
December 17, 2013
April 2011
July 2012   (final data collection date for primary outcome measure)
  • Maximum Observed Plasma Concentration (Cmax) of Iloperidone Divided by the Average Plasma Concentration (Cav) of Iloperidone (Cmax/Cav) - Phase B [ Time Frame: Pre-dose to 26 days post-dose ] [ Designated as safety issue: No ]
    Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
  • The Average Plasma Concentration (Cav) of Iloperidone - Phase C [ Time Frame: Pre-dose to 26 days post-dose ] [ Designated as safety issue: No ]
    Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. Blood samples were collected after each depot injection. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Cav was calculated as AUC0-672h/672 h.
Safety and tolerability of iloperidone depot formulations as measured by adverse events, clinical safety labs, vital signs, electrocardiograms (ECGs), and injection site assessments [ Time Frame: up to 42 days after injection ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01348100 on ClinicalTrials.gov Archive Site
  • Time to Reach the Maximum Plasma Concentration (Tmax) of Iloperidone - Phase B [ Time Frame: Pre-dose to 26 days post-dose ] [ Designated as safety issue: No ]
    Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
  • Maximum Observed Plasma Concentration (Cmax) of Iloperidone - Phase B [ Time Frame: Pre-dose to 26 days post-dose ] [ Designated as safety issue: No ]
    Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
  • Area Under the Plasma Concentration-time Curve From 0 to the End of the Dosing Period (AUCtau) of Iloperidone - Phase B [ Time Frame: Pre-dose to 26 days post-dose ] [ Designated as safety issue: No ]
    Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. The area under the curve was calculated using a linear trapezoidal method. The end of the dosing period was 672 hours (28 days).
  • Area Under the Plasma Concentration-time Curve From 0 to the Last Measurable Concentration (AUClast) of Iloperidone - Phase B [ Time Frame: Pre-dose to 26 days post-dose ] [ Designated as safety issue: No ]
    Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. The area under the curve was calculated using a linear trapezoidal method.
  • The Average Plasma Concentration (Cav) of Iloperidone - Phase B [ Time Frame: Pre-dose to 26 days post-dose ] [ Designated as safety issue: No ]
    Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Cav was calculated as AUC0-672h/672 h.
  • Duration That the Concentration of Iloperidone Was Above 4 ng/mL (Teff) - Phase B [ Time Frame: Pre-dose to 26 days post-dose ] [ Designated as safety issue: No ]
    Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. The duration that the concentration of iloperidone was above 4 ng/mL was calculated by linear interpolation. PK/pharmacodynamic analysis performed in other studies suggests that iloperidone plasma levels of 4 ng/mL or above provide clinical efficacy.
  • Time to Reach the Maximum Plasma Concentration (Tmax) of Iloperidone - Phase C [ Time Frame: Pre-dose to 26 days post-dose ] [ Designated as safety issue: No ]
    Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. Blood samples were collected after each depot injection. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
  • Maximum Observed Plasma Concentration (Cmax) of Iloperidone - Phase C [ Time Frame: Pre-dose to 26 days post-dose ] [ Designated as safety issue: No ]
    Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. Blood samples were collected after each depot injection. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
  • Area Under the Plasma Concentration-time Curve From 0 to the End of the Dosing Period (AUCtau) of Iloperidone - Phase C [ Time Frame: Pre-dose to 26 days post-dose ] [ Designated as safety issue: No ]
    Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. Blood samples were collected after each depot injection. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. The area under the curve was calculated using a linear trapezoidal method. The end of the dosing period was 672 hours (28 days).
  • The Average Plasma Concentration (Cav) of Iloperidone Divided by Dose - Phase C [ Time Frame: Pre-dose to 26 days post-dose ] [ Designated as safety issue: No ]
    Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. Blood samples were collected after each depot injection. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Cav was calculated as AUC0-672h/672 h.
Pharmacokinetic profile of iloperidone depot formulations as measured by concentrations of iloperidone in the blood [ Time Frame: up to 42 days after injection ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Two Iloperidone Depot Formulations Followed by a Dose-ranging Phase of One Selected Formulation in Schizophrenic Patients Given Depot Injections Every 28 Days

This study is designed as a 3-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare 2 depot dosage forms, and perform dose ranging of 1 chosen form in support of a monthly depot dosing regimen. In Phase A, the study is designed to evaluate the safety of a crystalline iloperidone depot formulation. In Phase B, the pharmacokinetic and safety profile of 2 depot clinical dosage forms will be compared, and 1 form will be selected for assessment in Phase C. Phase C of this study is designed to define the dose-exposure relationship of the selected form and to provide information that will permit a comparison of the risk-benefit ratio of several doses of the study drug to enable optimal dose selection for later studies.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Schizophrenia
  • Drug: Iloperidone crystalline formulation
    Iloperidone was formulated as 100 µm crystals for IM depot injection.
  • Drug: Iloperidone microparticle formulation
    Iloperidone was formulated as microparticles for IM depot injection.
  • Drug: Oral iloperidone
    Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.
  • Experimental: Iloperidone 50 mg crystalline formulation - Phase A
    Participants received a crystalline formulation of iloperidone 50 mg in a depot intramuscular (IM) injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
    Interventions:
    • Drug: Iloperidone crystalline formulation
    • Drug: Oral iloperidone
  • Experimental: Iloperidone 125 mg crystalline formulation - Phase A
    Participants received a crystalline formulation of iloperidone 125 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
    Interventions:
    • Drug: Iloperidone crystalline formulation
    • Drug: Oral iloperidone
  • Experimental: Iloperidone 250 mg crystalline formulation - Phase B
    Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
    Interventions:
    • Drug: Iloperidone crystalline formulation
    • Drug: Oral iloperidone
  • Experimental: Iloperidone 250 mg microparticle formulation - Phase B
    Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
    Interventions:
    • Drug: Iloperidone microparticle formulation
    • Drug: Oral iloperidone
  • Experimental: Iloperidone 250 mg microparticle formulation - Phase C
    Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
    Interventions:
    • Drug: Iloperidone microparticle formulation
    • Drug: Oral iloperidone
  • Experimental: Iloperidone 500 mg microparticle formulation - Phase C
    Participants received a microparticle formulation of iloperidone 500 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
    Interventions:
    • Drug: Iloperidone microparticle formulation
    • Drug: Oral iloperidone
  • Experimental: Iloperidone 625 mg microparticle formulation - Phase C
    Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
    Interventions:
    • Drug: Iloperidone microparticle formulation
    • Drug: Oral iloperidone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
81
July 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with schizophrenia that have been stable for 3 months.

Exclusion Criteria:

  • Women who can become or are currently pregnant or lactating.
  • Hypersensitivity to iloperidone or related drugs.

Other protocol-defined inclusion/exclusion criteria may apply.

Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01348100
CILO522E2101
Not Provided
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Vanda Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP